ClinicalTrials.gg
CompletedNCT02106182BPHUpdated Mar 10, 2017

Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

A Phase 4 interventional study of Silodosin and Laboratory tests in Nocturia and Benign Prostatic Hyperplasia, sponsored by JW Pharmaceutical. Completed at 6 sites in Korea, Republic of. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Study summary

The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied by nocturia.

Read the detailed description

This study is designed as a multi-center, prospective, open-label and single-arm study. Subjects who are willing to provide written informed consent will be enrolled after screening for eligibility criteria. The subjects will be administered with investigational product for 12 weeks and visit as outpatients for evaluation of safety and efficacy at baseline (visit 2) and 4 weeks (visit 3) and 12 weeks (visit 4) after baseline.

02

Conditions studied

  • Nocturia
  • Benign Prostatic Hyperplasia

Keywords

  • Benign prostatic hyperplasia
  • Nocturia
  • Silodosin
  • Thrupas
03

In context

Nocturia

134 studies on the registry are indexed under Nocturia; 22 are open to participants now.

This study's enrollment of 135 is above the median of 71 across 108 interventional studies indexed under Nocturia.

Browse Nocturia studies →

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males of at least 50 years of age, with current diagnosis of benign prostatic hyperplasia
  • Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary
  • More than total of 8 points on IPSS and 3 points on QoL
  • Able to provide written and to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • PSA level > 10 ng/㎖ (except patients who had 4 ng/㎖ \< PSA level ≤ 10 ng/㎖ 6 months prior to screening and identified as negative from )
  • Symptoms of postural hypotension
  • Severe renal disorders or ≥ 2.0 mg/dL
  • Severe hepatic disorders or or ALT ≥ 3 x (ULN)
  • Severe cardiac disorders or development or diagnosis of vascular disorder (unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, coronary artery bypass graft, etc) 6 months prior to enrollment
  • Any disorder of the gastrointestinal system which could result in altered digestion or absorption, history of gastrointestinal tract surgery except ecphyadectomy
  • Patients with bladder cancer, cystolith or urethral stricture
  • Patients with neurogenic bladder
  • History of acute urinary retention
  • Indwelling catheter or self intermittent catheterization
  • Patients with pyuria 1 month prior to screening
  • History of prostatic cancer
  • History of prostatic surgery
  • Patients with uncontrolled chronic disease
  • Alcoholism or sustained drug dependent abuse 1 year prior to screening
  • to α1A-receptor blockers
  • Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride)
  • Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Silodosin

    Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks

    Drug: Silodosin · Other: Laboratory tests · Other: 3-days voiding diary · Other: 12 weeks

Interventions

  • Also known as: Thrupas Cap

  • OtherLaboratory tests

    Subject's overall health state will be evaluated by clinical laboratory tests. Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)

  • Other3-days voiding diary

    3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).

  • Other12 weeks
06

What researchers measure

Primary outcomes

  1. Incidence of nocturia

    Descriptive statistics for incidence of nocturia will be provided for each visit. Paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

Secondary outcomes

  1. Mean change in International Prostate Symptom Score(IPSS) from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  2. Mean change in Quality of Life(QoL) scores from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  3. Mean change in Overactive Bladder Symptom Score(OABSS) from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  4. Mean change in International Consultation on Incontinence modular Questionnaire-Nocturia(ICIQ-N) from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  5. Mean change in Questions 3, 5 and 6 (voiding symptoms) of IPSS from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  6. Mean change in Question 1 (postvoiding symptoms) of IPSS from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  7. Mean change in Questions 2, 4 and 7 (storage symptoms) from baseline

    Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.

    Time frame: 12 weeks

  8. Ratio of subjects with ≥ 25% decrease in incidence of nocturia

    Time frame: 12 weeks

  9. Ratio of subjects with ≥ 25% decrease in IPSS

    Time frame: 12 weeks

07

Study locations

6 sites
  • Bucheon St.Mary's Hospital
    Bucheon, Gyeonggi-do 420-818, Korea, Republic of
  • Ajou University Hospital
    Suwon, Gyeonggi-do 443-380, Korea, Republic of
  • Pusan Natonal University Hospital
    Busan, 602-739, Korea, Republic of
  • Eulji University Hospital
    Daejeon, 302-799, Korea, Republic of
  • Hanyang University Hospital
    Seoul, 133-792, Korea, Republic of
  • Soon Chun Hyang University Hospital
    Seoul, 140-887, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Mar 2016, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 8, 2014
StartActual
Jan 2, 2014
Primary completionActual
Mar 2, 2016
CompletionActual
Aug 1, 2016
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02106182
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
Jan 2, 2014
Primary completion
Mar 2, 2016
Completion
Aug 1, 2016
Last update
Mar 10, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion